ACE2 Gender Differences in Stroke With COVID-19

Plain-language summary

This study examined ACE2-related gender differences in patients who had a stroke, in the context of COVID-19, using robot-assisted rehabilitation together with epigenetic and biochemical analyses. People with a stroke confirmed by MRI or CT and within 6 months of the stroke could take part. This study without an assigned phase has been carried out and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Fondazione Don Carlo Gnocchi Onlus

Intervention

Robotic assisted intervention, epigenetic analyses, biochemical analyses

Start date

9/4/2020

Estimated completion

1/31/2023

Countries

Italy

Related genes

Locations

• Rome, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* stroke patients (hemorrhagic or ischemic) documented through Magnetic Resonance Imaging (MRI) or Computed Tomography (CT);
* NeuroCOVID19 stroke patients with double nasopharyngeal swab negative after 24 hours for SARS-Cov2.
* latency time within 6 months after stroke event;
* sufficient cognitive and language skills to understand the instructions related to the administration of the assessment scales and to sign informed consent;

Exclusion Criteria:

* behavioral and cognitive disorders that may interfere with the therapeutic activity;
* other orthopaedic or neurological complications that may interfere with the rehabilitation protocol;
* inability to understand and sign informed consent;